loading...| Preferred Name |
Tocilizumab |
|
| Synonyms |
IL-6 receptor monoclonal antibodies: tocilizumab Tocilizumab Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer TOCILIZUMAB Actemra MRA R-1569 RoActemra |
|
| Definitions |
A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C84217 |
|
| Accepted_Therapeutic_Use_For |
Treatment of COVID-19-emergency use authorization (EUA). |
|
| CAS_Registry |
375823-41-9 |
|
| CHEBI_ID |
CHEBI:64360 |
|
| code |
C84217 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191670 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191200 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191387 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191404 |
|
| Contributing_Source |
ACC/AHA CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions. |
|
| Display_Name |
Tocilizumab |
|
| FDA_UNII_Code |
I031V2H011 |
|
| FULL_SYN |
IL-6 receptor monoclonal antibodies: tocilizumab Tocilizumab Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer TOCILIZUMAB Actemra MRA R-1569 RoActemra |
|
| Has_ACC-AHA_SARS2_Authorized_Value |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17998 |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Tocilizumab |
|
| Maps_To |
Tocilizumab |
|
| NCI_Drug_Dictionary_ID |
713832 |
|
| PDQ_Closed_Trial_Search_ID |
713832 |
|
| PDQ_Open_Trial_Search_ID |
713832 |
|
| Preferred_Name |
Tocilizumab |
|
| prefixIRI |
Thesaurus:C84217 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1609165 |
|
| subClassOf |